INMB — Inmune Bio, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1711754 ·
Last close
$0.96
Market Cap
$29.72M
52W High
$2.60
52W Low
$0.89
ADV30
326,246
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -5,009,000 -4,722,000 21,508,000 16,329,000 3,435,000
Jun 2026 0 — -1,476,000 -1,273,000 26,845,000 18,411,000 6,483,000
Mar 2026 0 — -5,812,000 -5,407,000 25,818,000 21,358,000 6,194,000
Dec 2025 0 — -5,474,000 -5,264,000 32,351,000 24,751,000 8,827,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-14,961,000
Investing CF
$-336,000
Financing CF
$816,000
CapEx
$-336,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.54
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-215,717,000
Inventory
—
Receivables
$4,767,000
ST Investments
—
EBIT TTM
$-20,195,000
Pretax Income TTM
$-18,416,000
Interest Exp TTM
—
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
—
Free Cash Flow
$-10,046,875
Enterprise Value
$15,604,702
Total Cash
$18,411,000
Total Debt
$1,405,000
Shares Out
30,959,079
Trailing EPS
$-0.60
Book Value
$0.89
ROE
-74.8%
ROA
-39.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 50,000 -30,869,000 -45,933,000 32,351,000 8,827,000 23,524,000 -22,582,000
Dec 2024 14,000 -42,635,000 -42,082,000 39,562,000 7,465,000 32,097,000 -33,361,000
Dec 2023 155,000 -29,741,000 -30,008,000 57,001,000 18,862,000 38,139,000 -11,980,000
Dec 2022 374,000 -25,951,000 -27,299,000 81,795,000 21,691,000 60,104,000 -22,686,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-18,416,000
OpCashFlow TTM
—
Assets (Latest)
$26,845,000
Forward EPS
$-0.43

Max Pain — expiry 2027-03-19

max pain strike: $1.00 · spot: $1.03 · call oi: 1,097 · put oi: 73

Peers — same industry

TickerNameMarket CapLastDaily %
EXOZ EXOZYMES INC. $30.80M $3.31 —
SAEN Genenta Science S.p.A. $27.82M $0.58 —
CVM CEL SCI CORP $32.54M $1.85 —
PTHS Pelthos Therapeutics Inc. $26.89M $6.84 —
GNTA Genenta Science S.p.A. $33.03M $0.69 —

News headlines (Yahoo Finance, 1h cache)

INmune Bio (INMB) Q3 2026 Earnings Call Transcript
2026-11-06 17:17 · Yahoo
INmune Bio, Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
INmune Bio Inc (INMB) Q3 2026 Earnings Call Highlights: UK Approval Path for Ebstracell Narrows ...
2026-11-06 11:17 · Yahoo
INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update
2026-11-05 21:00 · Yahoo
INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th
2026-10-29 13:15 · Yahoo
INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement
2026-10-28 12:00 · Yahoo
Manufacturing Progress Gives INmune Bio a Clearer UK Filing Path for Ebstrocel
2026-10-21 18:28 · Yahoo
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
2026-10-21 11:15 · Yahoo
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
2026-10-21 11:00 · Yahoo
Can Quantum Computing (QUBT) Be A Bargain As Its INmune Bio Deal Opens Biopharma?
2026-10-16 04:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.